Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Schenkein

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
American Journal of Clinical Pathology|October 19, 2004
Targeted therapies for cancer 2004Jeffrey S Ross, David P Schenkein, Robert Pietrusko, et al.
The Journal of Experimental Medicine|February 10, 2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsStefan Gross, Rob A Cairns, Mark D Minden, et al.
Blood|November 16, 2014
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibitionAndrew Kernytsky, Fang Wang, Erica Hansen, et al.
The Oncologist|April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarateAmir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Cancer|October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myelomaJames R Berenson, Sundar Jagannath, Bart Barlogie, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Journal of Neuro-Oncology|October 22, 2011
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyWhitney B Pope, Robert M Prins, M Albert Thomas, et al.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Pathology|October 19, 2004
Targeted therapies for cancer 2004Jeffrey S Ross, David P Schenkein, Robert Pietrusko, et al.
The Journal of Experimental Medicine|February 10, 2010
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutationsStefan Gross, Rob A Cairns, Mark D Minden, et al.
Blood|November 16, 2014
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibitionAndrew Kernytsky, Fang Wang, Erica Hansen, et al.
The Oncologist|April 25, 2014
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarateAmir T Fathi, Hossein Sadrzadeh, Amy H Comander, et al.
Cancer|October 6, 2005
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myelomaJames R Berenson, Sundar Jagannath, Bart Barlogie, et al.
The New England Journal of Medicine|June 27, 2003
A phase 2 study of bortezomib in relapsed, refractory myelomaPaul G Richardson, Bart Barlogie, James Berenson, et al.
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.
The Oncologist|December 20, 2011
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingDarrell R Borger, Kenneth K Tanabe, Kenneth C Fan, et al.
Journal of Neuro-Oncology|October 22, 2011
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyWhitney B Pope, Robert M Prins, M Albert Thomas, et al.
Blood|October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Pageof 3